l

The content of this website is intended for healthcare professionals only

Return of skin cancer could be predicted by blood test

Early warning system for cancer return is possible

Adrian O'Dowd

Wednesday, 06 December 2017

Doctors testing the blood of patients with skin cancer for tumour DNA could predict the chances of an aggressive cancer returning, claims a new study* published in the Annals of Oncology.

Cancer Research UK scientists said their discovery could lead to identifying patients who are most at risk of their disease returning so they might benefit from new immunotherapy treatments.

Around 15,400 people in the UK are diagnosed with malignant melanoma each year and although survival has doubled in the last 40 years, around 2,500 people die from the disease annually in the UK.

Researchers based at the Cancer Research UK Manchester Institute and The Christie NHS Foundation Trust studied blood samples taken after surgery from 161 patients with stage 2 and 3 melanoma.

The samples were collected as part of the AVAST-M trial which compared bevacizumab compared with placebo in 1,343 patients with resected high-risk stage 2 and 3 melanoma.

The researcher then looked for faults in two genes that are linked to 70% of melanoma skin cancers – BRAF and NRAS.

Results showed that after five years, 33% of patients who had a positive blood test for faults in either of the two genes were alive, compared to 65% of those who did not.

The results also revealed that skin cancer was much more likely to return within a year of surgery in patients who had faults in either of the two genes.

Professor Richard Marais, lead researcher and director of the Cancer Research UK Manchester Institute, based at University of Manchester, said: “For some patients with advanced melanoma, their cancer will eventually return.

“We have no accurate tests to predict who these patients will be, so our findings are really encouraging. If we can use this tumour DNA test to accurately predict if cancer is going to come back, then it could help doctors decide which patients could benefit from new immunotherapies.

“These treatments can then reduce the risk of the cancer spreading. The next step is to run a trial where patients have regular blood tests after their initial treatment has finished in order to test this approach.”

Professor Karen Vousden, Cancer Research UK’s chief scientist, said: “Being able to develop an early warning system that will predict if a cancer will return could make a real difference to patients.

“Research like this shows that for some cancers, there may be ingenious solutions - such as a blood test. If follow up research shows that this test can be used to inform treatment decisions and improve outlook, it could be a game-changer in our ability to deal with advanced skin cancer.”

The study also involved researchers based at Warwick University, Oxford University and Cambridge University Hospital.


* Lee RJ, Gremel G, Marshall A, et al. Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. Annals of Oncology (2017). DOI:10.1093/annonc/mdx717

Registered in England and Wales. Reg No. 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Reg No. 30158470